Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients - Quiz - MDSpire

Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients

  • By

  • Yasuo Imanishi

  • Takumi Imai

  • Hisako Fujii

  • Rei Aida

  • Yuki Nagata

  • Tetsuo Shoji

  • Shinichiro Kashiwagi

  • Tsutomu Takashima

  • Masanori Emoto

  • January 15, 2025

  • 0 min

Share

Original Source(s)

Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients

  • by Yasuo Imanishi, Takumi Imai, Hisako Fujii, Rei Aida, Yuki Nagata, Tetsuo Shoji, Shinichiro Kashiwagi, Tsutomu Takashima, Masanori Emoto

  • January 15, 2025

Related Content

Diagnosis and treatment of breast cancer metastasis to thyroid: a case report and literature review

Evaluating the reliability and quality of osteoporosis content on TikTok and BiliBili: A cross-sectional content analysis

Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.